Experimental transplantation of human umbilical cord blood (hUCB) mononuclear cells (MNCs) in rodent stroke models revealed the therapeutic potential of these cells. However, effective cells within the heterogeneous MNC population and their modes of action are still under discussion. MNCs and MNC fractions enriched (CD34 + ) or depleted (CD34 − ) for CD34-expressing stem/progenitor cells were isolated from hUCB. Cells were transplanted intravenously following middle cerebral artery occlusion in spontaneously hypertensive rats and directly or indirectly cocultivated with hippocampal slices previously subjected to oxygen and glucose deprivation. Application of saline solution or a human T-cell line served as controls. In vivo, MNCs, CD34 + and CD34
INTRODUCTION
therapeutic mechanisms of cord blood cells applied after stroke still remain unclear. Intravenous administration reduced infarct volume and ameliorated behavioral defiTransplantation of human umbilical cord blood (hUCB) mononuclear cells (MNCs) for experimental cits following middle cerebral artery occlusion in rodents (40). With special relevance for stroke therapy, stroke therapy has been thoroughly investigated since a therapeutic impact of these cells was first reported (8) .
hUCB MNCs are effective when given in a clinically relevant time frame of 48 h (20), which is far beyond Numerous hUCB cell-mediated effects on postischemic cerebral tissue have been discovered, but the precise the 4.5-h time window for thrombolysis (13), currently 724 BOLTZE ET AL.
being the only effective stroke therapy in humans. Cord for preclinical stroke research (38) . Additionally, rodent hippocampal slice cultures were used to determine blood cell populations are further expected not to induce severe graft versus host disease in allogenic use. Cord effects of particular cell populations on neuronal survival after oxygen and glucose deprivation (OGD), also blood cells are also among the few stem cell containing populations allowing for autologous application and considering cell migration, direct and indirect application paradigms, and dose escalation effects. might therefore become of clinical relevance (24, 28, 45) .
The MNC fraction of hUCB is a heterogeneous popu-MATERIALS AND METHODS lation that was previously characterized elsewhere (35) . Prior to use, MNCs were rapidly thawed in phosphatelesion by immunohistochemistry and polymerase chain buffered saline (PBS) containing 75 U/ml DNase I reaction (40). However, Chen et al. (8) localized only (Roche Diagnostics, Germany) and rinsed in RPMI-0.3% of administered MNCs near the ischemic lesion 1640 (PAA, Germany). with rare signs of differentiation into neuronal tissue. A CD34 + cells were isolated from the MNC fraction by final proof for in vivo differentiation of hUCB cells into using the MACS immunomagnetic positive selection functional neurons following stroke is also lacking.
Preparation of Umbilical Cord Blood Samples
protocol (Miltenyi Biotech, Germany). Obtained cells Thus, it is more likely that cells influence the imbalwere analyzed using a FACSCalibur flow cytometer anced neuronal microenvironment after stroke than difequipped with the CellQuest TM software (both Bectonferentiating into functional brain tissue (21). There is Dickinson, USA) and characterized by anti-CD45-fluoresgrowing evidence that UCB cell therapy may exert neucein isothiocyanate (FITC) and anti-CD34-allophycocyanin roprotection by anti-inflammatory and immunomodulatantibodies (APC, both Beckman Coulter, Germany). Isoing effects (18, 19) . MNCs are also known to secrete type-identical monoclonal antibodies served as controls. numerous soluble factors as interleukin (IL)-8, macroAfter separation, CD34-enriched (CD34 + ) and CD34-phage chemoattractive protein-1 (21), , and depleted (CD34 − ) fractions contained 94.11 ± 3.42% or nerve growth factor (NGF) (6) Cell Transplantation occlusion (MCAO) was monitored in spontaneously hypertensive rats (SHR). These animals suffer from varAll experiments involving animals were approved by the local governmental commission for animal welfare. ious stroke-relevant comorbidities and are recommended Forty adult male spontaneously hypertensive/NCrl rats and contralateral ventricles were calculated slice-wise and interpolated to a volume using the Image J soft-(SHR, Charles River, Germany) were randomly assigned to five experimental groups (n = 8 each) and subjected ware and the YAWI 2D 1.3.2. selection tool (open source). Lesion size was estimated by the volume of the to permanent cortical MCAO. Briefly, animals were anaesthetized by intraperitoneal injection of ketamine diffusion disturbance added to the differences between the ipsilateral and contralateral ventricle. Day 1 values (100 mg/kg, Merial, Germany), xylacine (10 mg/kg, Bayer, Germany), and atropine (0.1 mg/kg, Ratiopharm, were set 100%. As a parameter for stroke-induced tissue loss, hemispherical atrophy was calculated from T2 Germany). Throughout the surgical procedure, core body temperature was continuously measured by a rectal images on day 29. For this, the volume of the ipsilateral hemisphere minus infarct and associated side ventricle probe and kept constant at 37°C using a feedback controlled warming pad (Fine Science Tools, Germany).
was divided by the volume of the contralateral hemisphere minus side ventricle. O 2 -enriched (35%) air was applied for breathing. After incision of the temporal muscle, the left MCA was Brain Tissue Analysis exposed by trepanation and local dura incision, and subsequently cauterized. After wound sealing, animals were After the last MRI on day 29 rats were sacrificed in deep anesthesia by transcardial perfusion using 40 ml of transferred back to their home cages and allowed to recover. Twenty-four hours after MCAO, animals PBS followed by 80 ml of 4% paraformaldehyde (PFA).
Brains were removed after decapitation and kept in 4% received intravenous injection of 1.0 ml PBS containing either 1 × 10 6 hUCB MNCs, CD34 Engineering, UK). Slices were then carefully transferred onto humidified 0.4-µm porous Millicell membrane above and placed on a laboratory-made rack that allowed positioning of the animal in the center of the inserts (Millipore, France) and maintained in 1 ml of serum-based medium (50% MEM-Hanks, 25% HBSS, static magnetic field. MRI was performed using a clinical standard Gyroscan Intera 1.5T scanner equipped 17 mM HEPES, 5 mM glucose, 1 mM L-glutamine, 25% horse serum, and 0.5% gentamycin) at 37°C for 3 days. with a 47-mm RF-coil (both Philips, The Netherlands). Spontaneous respiration was monitored throughout Thereafter, cultures were transferred to serum-free medium (horse serum replaced by 25% Neurobasal-A imaging by the breathing sensor of the scanner, which was placed under the subject's abdomen. T2-weighted and 0.5% B27; referred to as standard condition) and kept for 7 days at 37°C in 5% CO 2 . Twenty-four hours turbo spin echo sequences were performed consisting of 20 transverse slices (1 mm thickness; matrix: 244 × 244; before experimental use, 2 µl propidium iodide (PI; 1 mg/ml, Sigma, Germany) was added to the culture field of view: 50 µm). For analysis of ischemic damage, areas of the diffusion disturbance and both ipsilateral medium to exclude predamaged slices. 
Oxygen and Glucose Deprivation Injury
(1 × 10 6 ) were suspended in 100 µl medium and administered into the upper part of the migration chamber on For OGD, hippocampal slices were transferred to six-8-µm pore size cell culture inserts (Greiner, Germany). well plates containing 1 ml of 10 mM mannitol-containThis pore size requires active migration for the cells to ing glucose-free Ringer solution. Cultures were placed reach the lower compartment. Cells were allowed to in a gas-tight chamber at 37°C. Oxygen was replaced migrate for 4 h at 37°C and 5% CO 2 before inserts were by 95% N 2 and 5% CO 2 within 10 min and slices were removed and migrated MNCs were collected. Viability incubated for another 40 min. Untreated control cultures and numbers of migrated cells were determined using were maintained under standard conditions (see above) the trypan blue exclusion method and BD Truecount in a normoxic atmosphere for the same time.
Tubes ( col (36) . The trypan blue and Truecount Tube viability Analysis of Cellular Damage assays were performed immediately before the FACS experiments and so no additional live/dead gating was Damage was analyzed in the cornu ammonis (CA1-carried out. CA2-CA3) after slices have been incubated for 2 h with 1 mg/ml PI at 22, 46, or 70 h post-MNC administration.
Analysis of Human-and Rat-Soluble Mediators PI fluorescence was thereafter elicited at 546 nm and A total volume of 1 ml of coculture media supernarecorded at >610 nm on an inverted Nikon Eclipse tant per well was analyzed using an antibody array kit TE-2000 fluorescence microscope (4× magnification; (RayBiotech, USA) to profile human and rat trophic facNikon, Germany) and analyzed using an image analysis tors. Membranes for analysis of soluble factors were software (LUCIA M, Nikon). To ensure comparability plotted with antibodies against human brain-derived of data fluorimetric mean values of untreated OGD conneurotrophic factor (BDNF), NGF, epidermal growth trols obtained at day 1 were defined as 100%. All other factor (EGF), vascular endothelial growth factor (VEGF), data obtained were given as relative values. and insulin-like growth factor 1 (IGF-1), or against rat Descriptive Migration Assay and Quantitative Flow ciliary neurotrophic factor (CNTF), NGF, and VEGF.
Cytometric Analysis of Migrating MNCs
For methodological reasons, supernatants were pooled from six wells, each containing three slices. Samples MNCs were stained with CTO as stated above. Migration studies were performed using OGD and norwere centrifuged (400 × g, 10 min) and stored at −80°C. Double concentrated (3,400 × g, 20 min, Amicon Ultramoxic control slices after 3 days of maintenance using a Zeiss LSM Pascal 5 confocal laser scanning microscope 4, Millipore, Germany) supernatants from OGD cultures as well as supernatants after direct (2.5 × 10 4 ) and indi-(Zeiss, Germany; Plan Neofluar 20× or 40×).
For quantitative migration assessment, slices were rect (2.5 × 10 4 , 12.5 × 10 4 , 25 × 10 4 ) application of MNCs were investigated. Array analysis was performed collected and stored at −80°C until further use. After thawing, slices were homogenized using 70-µm cell according to manufacturer's instructions. Chemiluminescence of membranes was visualized in an Intelligent strainers (BD Falcon, USA). Extracts were dissolved in serum-free medium and protein concentration was Dark Box II (Fuji Photo Film, Germany) for 40 s. adjusted to 1 µg/ml. Five hundred microliters of homogStatistical Analysis enates was filled in the lower compartment of the migration chambers. Equal volumes of medium, supplemented
All results are reported as mean ± SD except for data on MNC migration and rat-soluble factors, which, for with 200 ng/ml recombinant stromal cell-derived factor (SDF; Immunotools, Germany) served as controls. MNCs methodological reasons, represent investigation of pooled samples. Analysis was performed using the SPSS subjects compared to hUCB cell subfraction-treated animals (p < 0.05 or less) on day 29 (Fig. 2B ). Administrastatistical software (version 11.5.1). After testing for Gaussian distribution, data of two independent variables tion of hUCB MNCs (5.2 ± 2.2%) diminished tissue loss more effectively than CD34 + cell application (9.6 ± 2.2%, were analyzed using Student's t-test for equally distributed data or the Mann-Whitney test (not normally disp < 0.05), but level of significance was not reached in comparison to CD34 − treatment (8.2 ± 2.3%, p = 0.057). tributed data), respectively. For three or more variables, ANOVA or ANOVA on ranks was performed followed Figure 2 also shows representative series of T2-weighted MR images at 20 h (Fig. 2C , prior to cell transplantaby post hoc analysis using Tukey's test. Values of p < 0.05 were considered to be statistically significant and tion) and on day 29 of hUCB cell-injected animals ( Fig.  2D ) as well as PBS/hT cell-treated subjects (Fig. 2E) . are indicated by single asterisks or alternative symbols (*, #, and §).
No signs of secondary bleeding, volume-consuming processes (like tumors), or infections were observed in any group at any time point. RESULTS
Improvement of Motor Function After Transplantation Detection of CFSE-Positive Cells From the Transplant of hUCB Cell Fractions
In Vivo MCAO caused distinct motor deficits as indicated by
No CFSE fluorescence indicating transplanted cells a pronounced decrease of RotaRod performance on day could be detected in any subject of any group on day 29 1. Control animals, but not hT cell-treated subjects, (data not shown). Thus, cells were most likely not presshowed a slow and limited spontaneous recovery over ent in the recipient brains 1 month after transplantation. time. Functional deficits were more effectively diminished in all subjects treated with hUCB-derived cell pop-
Reduction of OGD-Induced Damage in Hippocampal ulations. This was evident from day 17 onwards for
Slices After Cell Application hUCB MNCs (p < 0.05 or less) (Fig. 1A) ) and of a hT cell line mance of hT cell-administered animals was inferior to by semiquantitative analysis of PI staining after OGD. all hUCB-treated subjects from day 7 on (p < 0.01), as
As indicated by a strong increase in PI staining, OGD well as compared to control subjects on day 11 (p < induced broad cellular damage, which was found pre-0.05) and at the end of trial (p < 0.01) (Fig. 1A-D) .
dominantly in the pyramidal layer of the hippocampal Groups that received CD34
+ and CD34 − cell treatment slices. The degree of damage in untreated OGD controls performed very similarly throughout the observation remained stable throughout the whole exploration period period and almost reached baseline level on day 17 (Fig. (p > 0.95) (Fig. 3A, B) . Direct application of MNCs had 1B-D). hUCB MNC injected rats were even superior to a significant protective impact (p < 0.05) and reduced CD34 + -and CD34 − -treated subjects from day 17 cellular degeneration at every investigated time point onwards (p < 0.05 or less) (Fig. 1D) . (Fig. 3A, B) . Comparable to MNCs, the CD34 + fraction reduced hUCB Administration Reduces Lesion Size cell degeneration on day 1 and day 2 but failed to proand Hemispherical Atrophy After MCAO vide protection on day 3. On the other hand, depletion of CD34-expressing cells (CD34 − ) from the MNC fraction No differences were detected in absolute lesion volumes on day 1 (data not shown). In all experimental abolished reduction of neural damage, as indicated by more intense PI staining. When applied on damaged hipgroups, there was a relative reduction of lesion size on day 7 and day 29 post-MCAO ( Fig. 2A ) in relation to pocampal slices hT cells also did not reduce neural degeneration. Application of those cells even increased the lesion in T2 images obtained on day 1. No differences between groups were evident on day 7 (p > 0.4).
cell death on day 3 after OGD (p < 0.05) (Fig. 3A) . Lesion volume reduction on day 29 was more evident in
Influence of OGD-Damaged Hippocampal Tissue groups that received hUCB subfractions compared to on Migration of MNC Fractions PBS and hT cell treatment (p < 0.01) (Fig. 2A) . There was no significant difference between groups that were MNCs were labeled with CTO and applied onto mouse slices with transgenic neuronal expression of administered hUCB subsets or between the control and the hT-cell group. eYFP (Fig. 4) . Fluorescence microscopic evaluation revealed that direct application of MNCs onto damaged Hemispherical atrophy, as an indicator of MCAOcaused cerebral tissue loss, was most prominent in hT tissue caused more cells to adhere to the slice compared to application of the same MNC number on normoxic cell-treated (15.4 ± 4.5%) and control (14.0 ± 3.6%) hippocampal tissue (Fig. 4A vs. B) . MNCs remained A migration assay using supernatants of homogenized organotypic cultures (22) was used to obtain informorphologically unchanged when cocultivated with normoxic control slices, but frequently converted from mation about the cell subsets migrating into lesioned hippocampal tissue. In this assay, normoxic control tisround to an elongated phenotype when applied onto OGD slices (Fig. 4C) . In addition, three-dimensional sue (undamaged) and tissue that underwent OGD prior to homogenization induced migration of a comparable confocal analyses showed that MNCs preferentially invaded the ischemically damaged nervous tissue (Fig.  number of cells (Fig. 4G ), which were significantly different from control medium (p < 0.05). In a positive 4D, E). In contrast, MNCs predominantly remained at the slice surface when applied onto normoxic control control assay addition of SDF-1 (CXCL-12), a potent chemoattractant for hematopoetic stem and progenitor slices (Fig. 4D , E vs. F).
cells (1), monocytes and lymphocytes (4), markedly
setups, T cells were the most prominent fraction within migrated MNCs (Fig. 4H , note logarithmic scale). Relainduced migration of MNCs towards the lower chamber of the culture system (p < 0.01) (Fig. 4G) − , and hT cells following OGD in hippocampal slices. After oxygen-glucose deprivation (OGD), 2.5 × 10 4 cells of each fraction were directly applied onto OGD slices. Cellular degeneration in the cornu ammonis was assessed by propidium iodide (PI) fluorescence over 3 consecutive days in three separate experiments comprising six slices each. Fluorimetric values obtained from OGD slices without treatment at day 1 were set 100%. (A) All groups were compared to OGD without treatment (black bar) at day 1. Cellular damage remained stable in nontreated OGD controls (black bars). Application of MNCs and CD34 + cells diminished damage in comparison to OGD control at days 1 and 2 (p < 0.05) as indicated by reduced PI fluorescence intensity, being even indifferent from normoxic controls at these days (white bars, p > 0.4). In contrast, only MNCs were able to provide protection until the end of the observation period. CD34 − cells failed to prevent cell damage in the cornu ammonis while the application of hT cells even aggravated cellular damage at day 3 (p < 0.05). White bars represent PI fluorescence in normoxic control hippocampal slices. All bars represent relative mean values ± SD. (B) Representative fluorescence micrographs of rat hippocampi cultivated under normoxic conditions, after OGD with and without by MNC application. *p < 0.05 versus OGD without treatment (black bar). Scale bar: 500 µm.
Effects of Application Mode and Cell Dose on
Indirect cocultivation of the same number of MNCs used in the direct cocultivation paradigm (2.5 × 10 4 ) had Neurodegeneration in Hippocampal Slice Cultures a markedly lower protective effect as revealed by PI staining. In contrast to direct application, this effect MNC application effectively prevented neurodegeneration. We evaluated the role of direct cell contacts for could only be discriminated from spontaneous neurodegeneration in untreated OGD slices on day 2 (p < 0.05) mediation of the protective potential after OGD. For that reason, effectiveness of directly applied MNCs was (Fig. 5A) . To test whether this less pronounced effect could potentially be caused by lowered concentrations compared to indirect application. In the latter experiment, direct cell-cell interaction between damaged hipof soluble neuroprotective factors after indirect MNC application, rising numbers of cell were applied to pocampal tissue and MNCs was prevented, but exchange of soluble factors between compartments was allowed.
OGD-damaged slices (Fig. 5B) . Fivefold elevation of (Fig. 5B) . On day 2 after OGD, a further increase in the After intravenous transplantation into comorbid rats number of MNCs applied (25 × 10 4 ) caused an addi- (38) suffering from focal cerebral ischemia, hUCB tional significant reduction of PI staining (Fig. 5B) , MNC, CD34 + , and CD34 − populations were clearly able indicating a dose-dependent protection by indirectly to diminish sensorimotor deficits as evaluated in the applied MNCs.
RotaRod test. Behavioral improvement was detected from day 7 onwards and lasted until the end of the Expression of Neurotrophic Factors experiment. Findings were confirmed by MRI lesion volumetry and atrophy assessment, with differences Since evaluation of indirect application of MNCs between the hUCB cells and controls after 29, but not indicated a potential role for soluble protection providafter 7 days upon stroke onset. To our knowledge, this ing agents, MNC-induced changes in the expression of is the first direct in vivo comparison between hUCB human and rat derived trophic factors were analyzed.
MNCs and subfractions thereof. Changes in the expression of human trophic factors Necrotic cell death in the infarct core following ceresecreted by applied MNCs were not detectable because bral ischemia is an immediate event peaking within the concentrations of measured human factors (NGF, 4-12 h following stroke onset (3). Although reduction EGF, IGF-1, BDNF) were below the detection limit of of necrotic, PI-positive cells in hippocampal slices was the assay (40 pg/ml).
shown in this study when hUCB MNCs and CD34 + cells VEGF secretion from rat hippocampal tissue did not were administered immediately after OGD, cell adminischange after direct or indirect application of human tration after 24 h in vivo had most likely no effect on MNCs (Fig. 6, left) . Evaluation of rat NGF levels necrotic cell death. Any evidence for engraftment of revealed a reduction of NGF secretion from OGD slices administered cells was not observed in our study 1 after application of MNCs in all cocultivation paradigms month after transplantation. This does not exclude the (Fig. 6, right) . Rat CNTF was not secreted in measurable possibility of cells homing to the brain at early time amounts. Because analysis had to be carried out with points following administration. However, reduction of pooled samples to reach detection limits, descriptive stalesion size and brain atrophy most likely cannot be tistics was not applicable. explained by cell replacement or differentiation and might be due to prevention of secondary cell death fol-DISCUSSION lowing MCAO. Inflammatory and apoptotic processes Cell preparations from hUCB have emerged as a leading to secondary cell loss after stroke have also been highly promising tool for neural tissue protection and observed at later time points following stroke onset in promoted regeneration following cerebral ischemia and the penumbra and bordering areas (10, 43) , thus being stroke (24, 44) . However, the mode of action underlying excellent targets for neuroprotection. Preventing this the therapeutic potential is still a matter of debate. Some secondary damage could result in decreased lesion size investigators showed homing of CD34-enriched hUCB and brain atrophy even without generation of de novo cells to areas bordering the ischemic lesion (8) . Stem brain tissue. Neuroprotective abilities of hUCB MNCs cells within hUCB MNCs are in principle able to differwere previously shown by our group (15) and recently entiate into neural cells in vitro (12) and in vivo (46), published studies also reported anti-inflammatory effects but differentiation from hUCB MNCs into functional of the cells (18,19). Considering further that hUCB neural tissue following stroke remains unproven. MoreMNCs may prevent white matter damage upon ischemia over, neuronal differentiation of transplanted cells seems by interactions with the peripheral immune system (14), to be a very rare event (8) . In contrast, numerous findthe mentioned neuroprotective effects could reliably ings indicate that hUCB cells could limit the progress of explain both the observed functional improvement and degeneration by delivering trophic factors (2), by modulesion size reduction without detectable cell grafting. lation of the neuroinflammatory response (41), and by
The Role of hUCB CD34 + Cells activation of antiapoptotic pathways (9), thus emphasizin Poststroke Neuroprotection ing the neuroprotective capabilities of these cells. This study evaluated differences in the protective impact of Although to a smaller extent when compared to hUCB MNCs, purified CD34 + cells were able to induce hUCB cell subpopulations both in vivo and in vitro with emphasis on the role of CD34 + stem cells, direct and functional recovery and lesion size reduction in MCAO rats but only transiently provided protection in vitro. The indirect cocultivation, and dose-dependent effects to gain more information on relevant cell fractions and data obtained in our study are in partial contrast to the investigation of Taguchi and colleagues (37). This study their mode of action.
reported that CD34
+ cells from hUCB enhanced neovaslargest MCAO-induced lesions. This treatment also came along with largest hemispherical atrophy, although cularization as well as recruitment and survival of neural progenitor cells following focal cerebral ischemia. This the difference was not statistically significant (p > 0.05). A similar finding was reported for IL-17-producing Tled to cortical regeneration in the model used, a so far unparalleled observation. However, CD34
− cells did not cell subsets (32) . These findings clearly argue against hT cells as mediators of neuroprotection. Further studies have an obvious therapeutic benefit while hUCB MNCs have not been assessed. Albeit the therapeutic impact of should address the question whether T-cell depletion can enhance the therapeutic impact of hUCB cell preparahUCB CD34
+ was clearly shown in both approaches, there are major differences between the studies. First, tions after stroke. Experiments using enriched natural killer or B-cell populations may also be needed for clarithe motor defects induced in the Taguchi trial can be considered minor as mice showed rapid recovery from fication. Interestingly, application of CD34 − cells did not provide effective neuroprotection on hippocampal slices motor deficits, which is in contrast to our approach. This may hinder a direct comparison between both approaches.
after OGD, but resulted in functional improvement and lesion size reduction in vivo. This, at first glance, conNext, the Taguchi group used immunodeficient SCID mice. That is an important difference considering the tradictory result, may point to mechanisms influencing the progress of stroke occurring outside of the brain, fact that the therapeutic impact of hUCB MNCs and subpopulations may at least partially be related to moduwhich may not require the presence of CD34 + cells. First evidence for such a mechanism was given by Borlongan lation of inflammatory processes (41) and peripheral immune response following stroke (42 Two different cell application paradigms were used in the in vitro section of our study: (i) direct application described for purified hUCB CD133
+ stem cells, which were able to reduce hypoxia-induced cell death, but not of MNCs and (ii) separate cultivation of hippocampal slices and MNCs to detect neurotrophic effects provided to the extent of hUCB MNCs (27). The relatively small amount of both CD133 + and CD34 + cells among hUCB by soluble MNC-derived factors. MNCs indirectly cultivated with neuronal tissue provided less protection to MNCs also enhances the probability of a rather modulatory role during neuroprotection. It may be assumed that neural tissue when compared with direct application of equal cell numbers. This observation could be explained stem and progenitor cells within umbilical cord blood can induce beneficial effects following neuronal damage by concomitant action of soluble and cell contact-based effects. Possibly, diminished beneficial effects were when acting solely. But for optimal protection maintenance, another, probably mature, cell type might be caused by lower concentrations of soluble mediators being present when the cells where placed remote from important. This also points to potential synergistic modes of action between both cell populations, which the postischemic tissue. To test this hypothesis, we applied rising numbers of MNCs in the indirect cultivashould be addressed in further studies. tion setup. Using this approach we were able to achieve The Therapeutic Role of Other hUCB Cell Populations protective effects comparable to direct application, but Following Experimental Stroke only by using 5-and 10-fold greater cell numbers. This dose dependency further points to the action of soluble Our study revealed that hUCB MNCs are superior to other applied cell populations regarding postischemic factors as one main reason for the reduced neural damage. Moreover, an indirect mode of action strongly sugneuroprotection in vivo and in vitro. This indicates an important role of other hUCB MNC subpopulations. The gesting a crucial role of soluble factors has also been shown for bone marrow-derived stem cells (30) . main fraction of mature cells within hUCB MNCs are CD4 + T cells (7) . Jurkat hT cells used in our study are Migration of hUCB Cells After OGD characterized by expression of CD4 and secretion of interferon-γ (16). hT cells did not induce neuroprotecMigration studies showed that MNCs invaded the hippocampal tissue preferentially after OGD. SDF-1 tion and even exacerbated tissue damage on day 3 in vitro. In vivo, hT cell-transplanted animals performed (CXCL12) as a strong enhancer of cell recruitment was used to demonstrate the migratory potential of MNC inferior to control subjects and tended to develop the fractions. Application of supernatants gained from condemand to assess the influence of selection processes in future studies. trols or OGD did not influence the migrating proportion of most cell types with exception of CD34 + cells, which were attracted by ischemic damage of neuronal tissue.
Modulation of VEGF and NGF Secretion This process would contribute to their enrichment at by hUCB MNCs lesioned sites in vivo, a conclusion also drawn by other Previous results showed a markedly increased VEGF studies (25, 37 + cells was not observed in vivo, as NGF has been shown to reduce neuronal death in the was the case with all other applied cell populations. One gerbil hippocampus after ischemia (33) . Different from explanation could be that the positive sorting of cells VEGF, secretion of rat NGF was decreased after direct influenced their ability to actively migrate over longer or indirect MNC administration in our experiments. distances in vivo, but not over shorter distances as in Reduction of cell damage after MNC application could our in vitro approach. It could also be assumed that a possibly be associated with increased preservation of 29-day follow-up period in immunocompetent animals NGF receptive structures causing the observed decrease was too long to observe graft survival.
of unbound NGF in supernatants. More probably, NGF reduction was due to decreased secretion of NGF by Possible Influence of the Cell Selection Process glial cells shown to upregulate NGF expression after on Experimental Results ischemia-induced neuronal damage (17). In this case It could be speculated that the positive selection proobserved NGF reduction would account for reduced cess used in our approach may have limited the neuroneuronal damage and subsequently diminished glial actiprotective potential of CD34 + cells, thus making them vation after MNC application. unable to act to their full potential. For example, antibodies attached to the cell surface could reduce the CONCLUSIONS migration potential or trigger any kind of intracellular cascades that may have altered the neuroprotective abiliIn summary, the experiments described in this study indicate clear differences in neuroprotective capabilities ties of the cells. However, we did not find signs of cascade activation in a previous study using positively of hUCB cell subpopulations with the whole MNC fraction being the most potent population. CD34 + cells, as a selected CD133
+ hUCB cells (27). Positively selected and genetically engineered CD34 + cells were recently stem cell and progenitor-comprising fraction of hUCB MNCs, preferentially provide neuroprotection at early shown to have excellent homing abilities and a clear therapeutic impact after transient MCAO (23) . Neverstages following ischemia. CD34 + cells are able to specifically accumulate at damaged tissue sites, but are not theless, detrimental influences of positive selection cannot be ruled out in general by these observations and the most potent cell population concerning neuroprotection. MNCs promote neuroprotection at least partly by need to be addressed in studies especially designed to address this question. For example, positively selected mechanisms not requiring direct contact to injured neural cells. Moreover, there are indications for a mature cells could be added back to the MNC fraction. Controlled comparison against another MNC fraction directly cell type within hUCB MNCs influencing stroke progress outside the CNS. This leads to the assumptions of obtained from density gradient centrifugation can reveal whether or not migration kinetics and neuroprotective (i) synergistic modes of actions of hUCB MNCs subpopulations and (ii) of a brain-remote component of abilities of positively selected hUCB cell populations are altered in the particular disease model. Moreover, as neuroprotection. Together with the dose-dependent neuroprotective capacity of hUCB MNCs, this concept knowledge about potential influences of the selection processes will also be relevant for clinical translation of might also be relevant for therapy translation into the clinic. Application of selected hUCB cell subpopulations hUCB-based (or other) cell therapies, there is a clear
